scholarly journals Imaging agents for in vivo molecular profiling of disseminated prostate cancer - targeting EGFR receptors in prostate cancer: Comparison of cellular processing of [111In]-labeled affibody molecule ZEGFR:2377 and cetuximab

2011 ◽  
Vol 38 (4) ◽  
Author(s):  
Orlova
Keyword(s):  
Prostate Cancer ◽  
Molecular Profiling ◽  
Imaging Agents ◽  
Cancer Targeting ◽  
Affibody Molecule ◽  
Cellular Processing ◽  
Egfr Receptors

scholarly journals Evaluations of CRC2631 toxicity, tumor colonization, and genetic stability in the TRAMP prostate cancer model

2020 ◽  
Author(s):  
Robert A. Kazmierczak ◽  
Bakul Dhagat-Mehta ◽  
Elke Gulden ◽  
Li Lee ◽  
Lixin Ma ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Tumor Targeting ◽  
Cancer Targeting ◽  
Cancer Model ◽  
Significant Treatment ◽  
Tumor Tissues ◽  
Serovar Typhimurium ◽  
Sequencing Studies ◽  
Prostate Cancer Model

AbstractConventional cancer chemotherapies are not fully efficacious and do not target tumors, leading to significant treatment-related morbidities. A number of genetically attenuated cancer-targeting bacteria are being developed to safely target tumors in vivo. Here we report the toxicological, tumor-targeting, and efficacy profiles of Salmonella enterica serovar Typhimurium CRC2631 in a syngeneic and autochthonous TRAMP model of aggressive prostate cancer. CRC2631 preferentially colonize primary and metastatic tumors in the TRAMP animals. In addition, longitudinal whole genome sequencing studies of CRC2631 recovered from prostate tumor tissues demonstrate that CRC2631 is genetically stable. Moreover, tumor-targeted CRC2631 generates an anti-tumor immune response. Combination of CRC2631 with checkpoint blockade reduces metastasis burden. Collectively, these findings demonstrate a potential for CRC2631 in cancer immunotherapy strategies.

Evaluation of aptamer-modified prostate cancer targeting vector in vitro and in vivo

2017 ◽  
Vol 17 (3) ◽  
pp. 174-178
Author(s):  
YanKun GUO ◽  
◽  
Xin WU ◽  
Wei LIU ◽  
◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Targeting ◽  
Targeting Vector

629: Novel Laser Activated Gold Nanoshell Thermal Ablation of Human Prostate Cancer in Vivo

2007 ◽  
Vol 177 (4S) ◽  
pp. 210-211 ◽  
Author(s):  
Joshua M. Stern ◽  
Jennifer Stanfield ◽  
Jer-Tsang Hsieh ◽  
Jeffrey A. Cadeddu
Keyword(s):  
Prostate Cancer ◽  
Thermal Ablation ◽  
Human Prostate ◽  
Human Prostate Cancer ◽  
Gold Nanoshell

794: Valproic Acid Inhibits Prostate Cancer Cell Growth in Vitro and in Vivo

2006 ◽  
Vol 175 (4S) ◽  
pp. 257-257
Author(s):  
Jennifer Sung ◽  
Qinghua Xia ◽  
Wasim Chowdhury ◽  
Shabana Shabbeer ◽  
Michael Carducci ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Valproic Acid ◽  
Cell Growth ◽  
Cancer Cell ◽  
Prostate Cancer Cell ◽  
Cancer Cell Growth

790: BMP-7 is a Potent Inhibitor of Prostate Cancer Bone Metastasis in Vivo

2006 ◽  
Vol 175 (4S) ◽  
pp. 255-256
Author(s):  
Cyrill A. Rentsch ◽  
Jeroen Buijs ◽  
Geertje Van der Horst ◽  
Petra Van Overveld ◽  
Antoinette Wetterwald ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Metastasis ◽  
Potent Inhibitor

In vivo imaging reveals prostate pathology in the PTEN knockout murine model of prostate cancer

2016 ◽  
Author(s):  
Alysha Bhatti ◽  
Almeida Gilberto Serrano de ◽  
Serena Tommasini Ghelfi ◽  
Alwyn Dart ◽  
Anabel Varela-Carver ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Murine Model ◽  
In Vivo Imaging

Magnesium Chloride is an Effective Therapeutic Agent for Prostate Cancer

2018 ◽  
Vol 8 (1) ◽  
pp. 62 ◽  
Author(s):  
Julianna Maria Santos ◽  
Fazle Hussain
Keyword(s):  
Prostate Cancer ◽  
Magnesium Chloride ◽  
Epithelial Mesenchymal Transition ◽  
Chromatin Condensation ◽  
Myosin Ii ◽  
In Vivo Studies ◽  
Migration Speed ◽  
Mesenchymal Transition

Background: Reduced levels of magnesium can cause several diseases and increase cancer risk. Motivated by magnesium chloride’s (MgCl2) non-toxicity, physiological importance, and beneficial clinical applications, we studied its action mechanism and possible mechanical, molecular, and physiological effects in prostate cancer with different metastatic potentials.Methods: We examined the effects of MgCl2, after 24 and 48 hours, on apoptosis, cell migration, expression of epithelial mesenchymal transition (EMT) markers, and V-H+-ATPase, myosin II (NMII) and the transcription factor NF Kappa B (NFkB) expressions.Results: MgCl2 induces apoptosis, and significantly decreases migration speed in cancer cells with different metastatic potentials.  MgCl2 reduces the expression of V-H+-ATPase and myosin II that facilitates invasion and metastasis, suppresses the expression of vimentin and increases expression of E-cadherin, suggesting a role of MgCl2 in reversing the EMT. MgCl2 also significantly increases the chromatin condensation and decreases NFkB expression.Conclusions: These results suggest a promising preventive and therapeutic role of MgCl2 for prostate cancer. Further studies should explore extending MgCl2 therapy to in vivo studies and other cancer types.Keywords: Magnesium chloride, prostate cancer, migration speed, V-H+-ATPase, and EMT.

Sign in / Sign up

Export Citation Format

Share Document